Dr. Kyung Bo Kim’s research interests lie at the interface between chemistry and biology, primarily developing small molecules targeting the ubiquitin-proteasome pathway that can be used to unravel pathophysiological processes or treat human diseases. Specifically, Dr. Kim’s research is focused on the potential application of proteasome inhibitors for challenging, incurable disease states, such as neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, and age-related macular degeneration) and multiple myeloma (MM). Additional research interest is to develop immunoproteasome inhibitors (targeting the immunoproteasome catalytic subunits LMP2 and/or LMP7) with favorable pharmaceutical properties to treat chronic inflammatory disorders, such as inflammatory bowel disease (IBD) and other autoimmune diseases.